New England Journal of Medicine

Vivli announces new data sharing platform for clinical trials research

Tuesday, October 10, 2017

The Laura and John Arnold Foundation has recently donated $2 million in funds to Vivli, a Massachusetts nonprofit, for establishing a unique data sharing platform for use in clinical trials.
“This financial support allows us to quickly move to launch the platform in 2018,” said Dr. Ida Sim, Vivli co-founder and technical lead. “Vivli’s technology and coordinated policies and processes will lead to new scientific discoveries from integrating existing datasets.”

[Read More]

Clinical trials prove Canada’s VSV-EBOV Ebola vaccine safe and effective

Thursday, April 2, 2015

Canada’s VSV-EBOV Ebola vaccine proved to be safe and effective in a phase I clinical trial, according to findings published in the New England Journal of Medicine. These studies were performed at the Walter Reed Army Institute of Research and the National Institute of Allergy and Infectious Diseases to explore the experimental vaccine’s safety and what immune response it evokes when administered at different dosages.

[Read More]

Novartis publishes CTL019 data for acute lymphoblastic leukemia

Thursday, October 16, 2014

Novartis and the University of Pennsylvania‘s Perelman School of Medicine have announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor (CAR) therapy CTL019.

[Read More]

Spanish Myeloma Group study a treatment milestone

Monday, August 5, 2013

Early treatment of asymptomatic myeloma, which has a high risk of developing into active multiple myeloma, can significantly improve the course of the disease, delay progression and increase patient survival. These were the conclusions of a clinical trial carried out by the Spanish Myeloma Group (GEM-PETHEMA), which unites specialists from more than 80 Spanish hospitals, published in the August issue of The New England Journal of Medicine.

[Read More]